gastric cancer
Conditions
Interventions
Experiment group:Kangai injection 60ml ivgtt D1-10 Q21d, combined with Chemotherapy OFL: L-OHP 130mg/m2 ivgtt d1, CF 200mg ivgtt d1-5, 5-FU 500 mg/m2 ivgtt d1-5, Q21d
Control group:Chemotherapy OFL: L-OHP 130mg/m2 ivgtt d1, CF 200mg ivgtt d1-5, 5-FU 500 mg/m2 ivgtt d1-5, Q21d
Sponsors
Guang’anmen Hospital affiliatied to China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosis of gastric cancer according to pathology or cytology; (2) KPS>=60?; (3) Aged from 18 to 75 years old; (4) ANC>1.5*10^9/L, PLT>100*10^9/L, Hb>9.0g/dl, BIL at normal level or < 1.5 x ULN, AST (SGOT)ALT (SGPT) < 2.5 x ULN; SCr< 1.5 x ULN; (5) Signed informed consent, with good compliance.
Exclusion criteria
Exclusion criteria: (1) Pregnant or lactating women,psychotic patient; (2) Patients with severe,uncontrolled organic lesions or infection, such as decompensated heart, lung, kidney failure can lead to tolerance of chemotherapy; (3) using other experimental drugs or paticipate in other clinical trials at the same time; (4) patients allergic to the investigational product.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life, progression-free survival (PFS), Tumor Marker, Weight; | — |
Primary
| Measure | Time frame |
|---|---|
| Adverse Reaction; | — |
Countries
China
Contacts
Public ContactHongsheng Lin
Guang’anmen Hospital affiliatied to China Academy of Chinese Medical Sciences
Outcome results
None listed